Skinvisible Continues to Expand Its Marketing Efforts to Combat Bird Flu

Skinvisible Continues to Expand Its Marketing Efforts to Combat Bird Flu

January 25, 2007

Skinvisible's Hand Sanitizer Lotion, Which Kills the Bird
Flu Virus, H5N1, Gets Increased Exposure to Potential Asian
Distributors


    LAS VEGAS, Jan. 25 /Xinhua-PRNewswire/ -- Skinvisible
Pharmaceuticals, Inc. (OTC Bulletin Board: SKVI), incited
by the latest increase in worldwide news reports of a rise
in bird flu incidents, has expanded its marketing efforts
in Asia, effective immediately.  Skinvisible's
Chlorhexidine Antimicrobial Hand Sanitizer Lotion with its
patented delivery system Invisicare(R), can kill the Avian
Bird Flu virus, H5N1, with greater than 99.9 percent
inactivation -- according to studies conducted by Europe's
leading contract virology research company Retroscreen
Virology ( http://www.skinvisible.com ).  To effectively
facilitate our key corporate strategies in targeting the
Asian region, Skinvisible has retained Ms. Evelyn Lee as
our Regional Corporate Advisor (Hong Kong) to spearhead our
activities.  Ms. Lee in collaboration with our marketing
partner, EMD Chemicals Inc./Merck KGaA, Darmstadt, Germany
(Merck KGaA stock symbols Reuters: MRCG, Bloomberg: MRK GY,
Frankfurt Stock Exchange: ISIN: DE 000 659 9905 - WKN: 659
990) is introducing Skinvisible's Chlorhexidine
Antimicrobial Hand Sanitizer Lotion to potential licensees
and various governmental agencies.

    (LOGO: 
http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO )
    (LOGO: 
http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO
)

    "When large reputable publications like the Wall
Street Journal cite incident after incident of new cases of
the bird flu in Egypt, Japan, China, Indonesia, Vietnam and
Hong Kong, you have to take notice," said Terry
Howlett, President and CEO of Skinvisible.  "We at
Skinvisible know that our Chlorhexidine Antimicrobial Hand
Sanitizer Lotion, along with regular hand washing, reduces
the spread of this H5N1 virus.  The active ingredient in
Skinvisible's product is Chlorhexidine (klor-HEX-i-deen),
an easily tolerated and effective antiseptic that kills or
inhibits the growth of disease-causing bacteria, viruses
and other microorganisms, and is used for surgical scrubs,
skin wounds, germicidal hand rinse and antibacterial dental
rinse.  This compound is delivered via Skinvisible's
patented Invisicare(R) polymer delivery system.  Studies
have further shown that our product stays effective for up
to four hours and cannot be rubbed off or washed off."
 

    Skinvisible's Chlorhexidine Antimicrobial Hand
Sanitizer Lotion has recently received government approval
in Canada.  Mr. Howlett adds: "We, at Skinvisible,
continue our efforts around the globe to expand our reach. 
This has been an important objective for Skinvisible as its
business model is focused on licensing its proprietary
formulations with Invisicare(R) to Pharmaceutical companies
worldwide."   

    About Retroscreen Virology Ltd.

    London-based Retroscreen Virology is Europe's leading
contract virology research company, created in 1989 by
Professor John Oxford, a world-renowned influenza
virologist. Contact: Dr. Rob Lambkin-Williams, Tel:
44-20-7882-7966.

    About Skinvisible Pharmaceuticals, Inc.

    Skinvisible Pharmaceuticals is a
research-and-development company that has patented
Invisicare(R), an innovative polymer delivery system that
enhances the delivery of active ingredients for topical
skincare products. Skinvisible's primary marketing
objective is to license its technology to brand
manufacturers of Rx and OTC dermatological, medical,
cosmetic and skincare products. http://www.skinvisible.com
and http://www.invisicare.com .

    Forward-Looking Statements

    This press release contains `forward looking'
statements within the meaning of Section 21A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, and are
subject to the safe harbors created thereby.  Such
statements involve certain risks and uncertainties
associated with an emerging company.  Actual results could
differ materially from those projected in the forward
looking statements as a result of risk factors discussed in
Skinvisible, Inc. reports on file with the U.S. Securities
and Exchange Commission (including, but not limited to, a
report on Form 10QSB for the quarter ending September 30,
2006).


    For more information, please contact:

    Corporate Contact:
     Terry Howlett, President/CEO
     Skinvisible Pharmaceuticals, Inc                      
              
     Tel:   [phone] (USA)
     Email: [e-mail]	


SOURCE  Skinvisible Pharmaceuticals, Inc.